«

»

Biotech Wunderkind Raises $1.1 Billion To Fund Pharma Startups

Vivek Ramaswamy, a former hedge fund partner who went on to engineer one of the biggest biotech initial public offerings in history, has a new source of cash: his investment vehicle, Roivant Sciences, just raised $1.1 billion from investors including the Softbank Vision Fund and Dexcel Pharma.

Read the full post at Forbes - Pharma & Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive